Click here to go to the previous page
Current Role and Novel Uses of Other Cytotoxic Agents with Radiation
Program Code:
PRES200
Date:
Sunday, September 21, 2008
SPEAKER(S):
Click the plus sign to see more detailed information
about each speaker.
Dr. Brahmer is an active clinical leader in the treatment of lung cancer and mesothelioma at SKCCC. She is in charge organizing the multidisciplinary thoracic malignancy conference whose members meet weekly to discuss thoracic malignancy cases that need a multidisciplinary review/approach. She is also a part of the oncology pain team headed by Dr. Stuart Grossman.
|
Walter Curran, Chairman and Professor, Emory University School of Medicine
Dr. Ilson completed undergraduate training at the University of Connecticut. He entered an M.D., Ph.D. combined degree program at New York University and received a Masters and Ph.D. degree in Basic Science and M.D. Degree from NYU. He completed his internship and residency in internal medicine at Bellevue Hospital at NYU in New York. He then moved to Memorial Sloan-Kettering Cancer Center and completed a fellowship in medical oncology and hematology. He joined the staff in 1992, becoming a member of the GI Oncology Service in the Department of Medicine, under the direction of Dr. David Kelsen.
Dr. Ilson is now an attending physician and member at Memorial Hospital, and is associate professor of medicine at Weill-Cornell Medical College. His area of research interest is upper gastrointestinal cancer with a focus on esophageal cancer. His research has focused on the study of new agents in advanced disease, and the evaluation of novel agents in combined modality therapy programs in locally advanced disease. He sits on the GI committees of CALGB and RTOG, and the Upper GI Cancer Guidelines Committee of NCCN. He is chairman on the Intergroup Esophageal and Gastric Cancer Task Force Committee.
|
Dr. Willett is Professor and Chair of Radiation Oncology at Duke University Medical Center. He has served as Chair of the GI Cancer Subcommittee for the RTOG since 1999. His research interests include the use of novel agents with radiation therapy in GI malignancies and the multi-modality therapy of GI cancers. He has authored or co-authored over 225 publications and edited 3 text books in Radiation Oncology.
|